424 related articles for article (PubMed ID: 34439836)
1. Neutrophil in the Pancreatic Tumor Microenvironment.
Jin L; Kim HS; Shi J
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439836
[TBL] [Abstract][Full Text] [Related]
2. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
4. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
7. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
Front Immunol; 2021; 12():730746. PubMed ID: 34630409
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
10. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
11. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma.
Naso JR; Topham JT; Karasinska JM; Lee MKC; Kalloger SE; Wong HL; Nelson J; Moore RA; Mungall AJ; Jones SJM; Laskin J; Marra MA; Renouf DJ; Schaeffer DF
Cancer Med; 2021 Feb; 10(3):1155-1165. PubMed ID: 33372414
[TBL] [Abstract][Full Text] [Related]
12. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
13. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Yang J; Jiang Y; He R; Liu W; Yang M; Tao L; Fu X; Shen Y; Li J; Liu D; Huo Y; Zhang J; Hua R; Zhang Z; Sun Y
J Immunol Res; 2019; 2019():8656282. PubMed ID: 31583260
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Immunotherapies for Treating Pancreatic Cancer.
Wu AA; Jaffee E; Lee V
Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
[TBL] [Abstract][Full Text] [Related]
15. Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer.
Novak I; Yu H; Magni L; Deshar G
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233631
[TBL] [Abstract][Full Text] [Related]
16. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
[TBL] [Abstract][Full Text] [Related]
18. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
19. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
Chao T; Furth EE; Vonderheide RH
Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer.
Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z
Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]